2023-07-132024-03-312024-03-31false15000404SSRS Healthcare Ltd2024-10-23iso4217:GBPxbrli:pure150004042023-07-13150004042024-03-31150004042023-07-132024-03-31150004042023-07-12150004042023-07-12150004042023-07-122023-07-1215000404bus:SmallEntities2023-07-132024-03-3115000404bus:AuditExempt-NoAccountantsReport2023-07-132024-03-3115000404bus:FullAccounts2023-07-132024-03-3115000404bus:PrivateLimitedCompanyLtd2023-07-132024-03-3115000404core:WithinOneYear2024-03-3115000404core:AfterOneYear2024-03-3115000404core:WithinOneYear2023-07-1215000404core:AfterOneYear2023-07-1215000404core:ShareCapital2024-03-3115000404core:SharePremium2024-03-3115000404core:RevaluationReserve2024-03-3115000404core:OtherReservesSubtotal2024-03-3115000404core:RetainedEarningsAccumulatedLosses2024-03-3115000404core:ShareCapital2023-07-1215000404core:SharePremium2023-07-1215000404core:RevaluationReserve2023-07-1215000404core:OtherReservesSubtotal2023-07-1215000404core:RetainedEarningsAccumulatedLosses2023-07-1215000404core:LandBuildings2024-03-3115000404core:PlantMachinery2024-03-3115000404core:Vehicles2024-03-3115000404core:FurnitureFittings2024-03-3115000404core:OfficeEquipment2024-03-3115000404core:NetGoodwill2024-03-3115000404core:IntangibleAssetsOtherThanGoodwill2024-03-3115000404core:ListedExchangeTraded2024-03-3115000404core:UnlistedNon-exchangeTraded2024-03-3115000404core:LandBuildings2023-07-1215000404core:PlantMachinery2023-07-1215000404core:Vehicles2023-07-1215000404core:FurnitureFittings2023-07-1215000404core:OfficeEquipment2023-07-1215000404core:NetGoodwill2023-07-1215000404core:IntangibleAssetsOtherThanGoodwill2023-07-1215000404core:ListedExchangeTraded2023-07-1215000404core:UnlistedNon-exchangeTraded2023-07-1215000404core:LandBuildings2023-07-132024-03-3115000404core:PlantMachinery2023-07-132024-03-3115000404core:Vehicles2023-07-132024-03-3115000404core:FurnitureFittings2023-07-132024-03-3115000404core:OfficeEquipment2023-07-132024-03-3115000404core:NetGoodwill2023-07-132024-03-3115000404core:IntangibleAssetsOtherThanGoodwill2023-07-132024-03-3115000404core:ListedExchangeTraded2023-07-132024-03-3115000404core:UnlistedNon-exchangeTraded2023-07-132024-03-3115000404core:MoreThanFiveYears2023-07-132024-03-3115000404core:Non-currentFinancialInstruments2024-03-3115000404core:Non-currentFinancialInstruments2023-07-1215000404dpl:CostSales2023-07-132024-03-3115000404dpl:DistributionCosts2023-07-132024-03-3115000404core:LandBuildings2023-07-132024-03-3115000404core:PlantMachinery2023-07-132024-03-3115000404core:Vehicles2023-07-132024-03-3115000404core:FurnitureFittings2023-07-132024-03-3115000404core:OfficeEquipment2023-07-132024-03-3115000404dpl:AdministrativeExpenses2023-07-132024-03-3115000404core:NetGoodwill2023-07-132024-03-3115000404core:IntangibleAssetsOtherThanGoodwill2023-07-132024-03-3115000404dpl:GroupUndertakings2023-07-132024-03-3115000404dpl:ParticipatingInterests2023-07-132024-03-3115000404dpl:GroupUndertakingscore:ListedExchangeTraded2023-07-132024-03-3115000404core:ListedExchangeTraded2023-07-132024-03-3115000404dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-07-132024-03-3115000404core:UnlistedNon-exchangeTraded2023-07-132024-03-3115000404dpl:CostSales2023-07-122023-07-1215000404dpl:DistributionCosts2023-07-122023-07-1215000404core:LandBuildings2023-07-122023-07-1215000404core:PlantMachinery2023-07-122023-07-1215000404core:Vehicles2023-07-122023-07-1215000404core:FurnitureFittings2023-07-122023-07-1215000404core:OfficeEquipment2023-07-122023-07-1215000404dpl:AdministrativeExpenses2023-07-122023-07-1215000404core:NetGoodwill2023-07-122023-07-1215000404core:IntangibleAssetsOtherThanGoodwill2023-07-122023-07-1215000404dpl:GroupUndertakings2023-07-122023-07-1215000404dpl:ParticipatingInterests2023-07-122023-07-1215000404dpl:GroupUndertakingscore:ListedExchangeTraded2023-07-122023-07-1215000404core:ListedExchangeTraded2023-07-122023-07-1215000404dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-07-122023-07-1215000404core:UnlistedNon-exchangeTraded2023-07-122023-07-1215000404core:NetGoodwill2024-03-3115000404core:IntangibleAssetsOtherThanGoodwill2024-03-3115000404core:LandBuildings2024-03-3115000404core:PlantMachinery2024-03-3115000404core:Vehicles2024-03-3115000404core:FurnitureFittings2024-03-3115000404core:OfficeEquipment2024-03-3115000404core:AfterOneYear2024-03-3115000404core:WithinOneYear2024-03-3115000404core:ListedExchangeTraded2024-03-3115000404core:UnlistedNon-exchangeTraded2024-03-3115000404core:ShareCapital2024-03-3115000404core:SharePremium2024-03-3115000404core:RevaluationReserve2024-03-3115000404core:OtherReservesSubtotal2024-03-3115000404core:RetainedEarningsAccumulatedLosses2024-03-3115000404core:NetGoodwill2023-07-1215000404core:IntangibleAssetsOtherThanGoodwill2023-07-1215000404core:LandBuildings2023-07-1215000404core:PlantMachinery2023-07-1215000404core:Vehicles2023-07-1215000404core:FurnitureFittings2023-07-1215000404core:OfficeEquipment2023-07-1215000404core:AfterOneYear2023-07-1215000404core:WithinOneYear2023-07-1215000404core:ListedExchangeTraded2023-07-1215000404core:UnlistedNon-exchangeTraded2023-07-1215000404core:ShareCapital2023-07-1215000404core:SharePremium2023-07-1215000404core:RevaluationReserve2023-07-1215000404core:OtherReservesSubtotal2023-07-1215000404core:RetainedEarningsAccumulatedLosses2023-07-1215000404core:NetGoodwill2023-07-1215000404core:IntangibleAssetsOtherThanGoodwill2023-07-1215000404core:LandBuildings2023-07-1215000404core:PlantMachinery2023-07-1215000404core:Vehicles2023-07-1215000404core:FurnitureFittings2023-07-1215000404core:OfficeEquipment2023-07-1215000404core:AfterOneYear2023-07-1215000404core:WithinOneYear2023-07-1215000404core:ListedExchangeTraded2023-07-1215000404core:UnlistedNon-exchangeTraded2023-07-1215000404core:ShareCapital2023-07-1215000404core:SharePremium2023-07-1215000404core:RevaluationReserve2023-07-1215000404core:OtherReservesSubtotal2023-07-1215000404core:RetainedEarningsAccumulatedLosses2023-07-1215000404core:AfterOneYear2023-07-132024-03-3115000404core:WithinOneYear2023-07-132024-03-3115000404core:Non-currentFinancialInstrumentscore:CostValuation2023-07-132024-03-3115000404core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-07-132024-03-3115000404core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-07-132024-03-3115000404core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-07-132024-03-3115000404core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-07-132024-03-3115000404core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-07-132024-03-3115000404core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-07-132024-03-3115000404core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-07-132024-03-3115000404core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-07-132024-03-3115000404core:Non-currentFinancialInstrumentscore:CostValuation2024-03-3115000404core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-03-3115000404core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-03-3115000404core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-03-3115000404core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-03-3115000404core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-03-3115000404core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-03-3115000404core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-03-3115000404core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-03-3115000404core:Non-currentFinancialInstrumentscore:CostValuation2023-07-1215000404core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-07-1215000404core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-07-1215000404core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-07-1215000404core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-07-1215000404core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-07-1215000404core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-07-1215000404core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-07-1215000404core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-07-1215000404bus:Director12023-07-132024-03-31

SSRS Healthcare Ltd

Registered Number
15000404
(England and Wales)

Unaudited Financial Statements for the Period ended
31 March 2024

SSRS Healthcare Ltd
Company Information
for the period from 13 July 2023 to 31 March 2024

Director

Dr Sammy Sarai

Registered Address

Fulford Lodge 1 Heslington Lane
Fulford
York
YO10 4HW

Registered Number

15000404 (England and Wales)
SSRS Healthcare Ltd
Statement of Financial Position
31 March 2024

Notes

2024

£

£

Current assets
Debtors37,579
Cash at bank and on hand19,703
27,282
Creditors amounts falling due within one year4(14,827)
Net current assets (liabilities)12,455
Total assets less current liabilities12,455
Net assets12,455
Capital and reserves
Called up share capital100
Profit and loss account12,355
Shareholders' funds12,455
The financial statements were approved and authorised for issue by the Director on 23 October 2024, and are signed on its behalf by:
Dr Sammy Sarai
Director
Registered Company No. 15000404
SSRS Healthcare Ltd
Notes to the Financial Statements
for the period ended 31 March 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 Section 1A, The Financial Reporting Standard applicable in the UK and Republic of Ireland.
Basis of preparation
The financial statements have been prepared on the historical cost basis.
Functional and presentation currency
The financial statements are presented in sterling, which is the functional currency of the entity.
Going concern
The UK economy has recently been impacted by rising inflation, interest rates and energy costs, exacerbated by the war in Ukraine. All these matters have impacted the company's trading results to a greater or lesser extent. At the date of signing these financial statements, the directors have considered the effect of these matters on the company with the information available to it and do not believe that it will affect the ability of the company to continue to trade for the foreseeable future. On this basis, the directors have prepared these financial statements on a going concern basis.
Turnover policy
The revenue shown in the profit and loss account represents income receivable from dental treatments carried out during the period. Revenue in respect of dental treatment uncompleted at the year end date is recognised by reference to the state of completion.
Current taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amount of tax expected to pay or recover using the tax rates and laws that have been enacted, or substantively enacted, at the reporting date.
Trade and other debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Trade and other creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Share capital
Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.
2.Average number of employees

2024
Average number of employees during the year1
3.Debtors: amounts due within one year

2024

£
Trade debtors / trade receivables7,579
Total7,579
4.Creditors: amounts due within one year

2024

£
Taxation and social security14,082
Other creditors51
Accrued liabilities and deferred income694
Total14,827
5.Related party transactions
During the year, the director loaned the company £51. Interest was accrued on the loan balance each month and applied at the UK market rate. This loan is repayable upon demand.